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Association Between Helicobacter pylori Infection and
Inflammatory Bowel Disease: A Meta-analysis and
Systematic Review of the Literature
Jay Luther, MD,* Maneesh Dave, MD,† Peter D.R. Higgins, MD, PhD,* and John Y. Kao, MD*
Background: Epidemiologic data suggest a protective effect of
Helicobacter pylori infection against the development of autoim-
mune disease. Laboratory data illustrate H. pylori’s ability to induce
immune tolerance and limit inflammatory responses. Numerous
observational studies have investigated the association between H.
pylori infection and inflammatory bowel disease (IBD). Our aim was
to perform a systematic review and meta-analysis of this association.
Methods: Medline, EMBASE, bibliographies, and meeting
abstracts were searched by 2 independent reviewers. Of 369 abstracts
reviewed, 30 promising articles were reviewed in detail. Twenty-
three studies met our inclusion criteria (subject N ¼ 5903). Meta-
analysis was performed with the metan command in Stata 10.1.
Results: Overall, 27.1% of IBD patients had evidence of infec-
tion with H. pylori compared to 40.9% of patients in the control
group. The estimated relative risk of H. pylori infection in IBD
patients was 0.64 (95% confidence interval [CI]: 0.54–0.75).
There was significant heterogeneity in the included studies that
could not be accounted for by the method of IBD and H. pylori
diagnosis, study location, or study population age.
Conclusions: These results suggest a protective benefit of H. pylori
infection against the development of IBD. Heterogeneity among stud-
ies and the possibility of publication bias limit the certainty of this
finding. Further studies investigating the effect of eradication of
H. pylori on the development of IBD are warranted. Because environ-
mental hygiene and intestinal microbiota may be strong confounders,
further mechanistic studies in H. pylori mouse models are also neces-
sary to further define the mechanism of this negative association.
(Inflamm Bowel Dis 2010;16:1077–1084)
Key Words: Helicobacter pylori, inflammatory bowel disease,
Crohn’s disease, ulcerative colitis
I nflammatory bowel disease (IBD) is a growing world-wide health burden.1,2 Specifically, many developing
countries have seen a dramatic rise in the incidence of IBD
since 1990.2–7 This rise may partially be accounted for by
the implementation of improved diagnostic methods and
heightened awareness of IBD.1,3 Furthermore, improved
access to a cleaner environment and the resulting decreased
incidence of common childhood infections may be contrib-
uting as well by altering one’s susceptibility to certain dis-
eases with an autoimmune component, such as IBD.8,9
Importantly, this suggests a possible protective benefit of
microbial infection during childhood.
Helicobacter pylori has coexisted with the human
race for over 50,000 years.10,11 It is an infection acquired
early in childhood, and if not eliminated by antimicrobial
therapy, is carried throughout life, producing symptoms in
only a minority.12,13 Recent epidemiological data suggests
a possible protective benefit of H. pylori colonization
against the development of certain diseases with an auto-
immune component, such as asthma.14,15 Furthermore,
there is emerging laboratory evidence illustrating H. pylori’s
role in the regulation of the immune system. Specifically,
H. pylori has been associated with increased gastric muco-
sal expression of Foxp3 (a T-regulatory cell marker) and
has shown the ability to skew the host immunologic tone
away from inflammatory Th1/Th17 responses (Fig. 1).16–21
Finally, IBD is more prevalent in areas with lower rates of
H. pylori colonization, such as in the United States.22
In fact, there is a steady rise in the incidence of IBD in
H. pylori endemic regions that corresponds to the
beginning of anti-H. pylori therapy for peptic ulcer
disease.2
To further investigate the possible association
between H. pylori infection and IBD, we conducted a sys-
tematic review and meta-analysis to estimate the relative
risk of H. pylori infection in patients with and without
IBD. Given the epidemiological and laboratory data previ-
ously cited, we hypothesized an inverse relationship
between H. pylori infection and IBD.
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MATERIALS AND METHODS
Search Strategy
This review was performed according to the standard
guidelines for meta-analyses and systematic reviews of
observational studies.23 To find relevant articles for this
review, we searched the following databases (from incep-
tion to March 2009): MEDLINE, EMBASE, Google
Scholar, the Cochrane Central Register of Controlled Tri-
als, ACP Journal Club, DARE, CMR, and HTA. The
search strategy used free-text words and MeSH terms to
increase the sensitivity of the search. The following search
terms were used: ‘‘inflammatory bowel disease,’’ ‘‘crohn’s
disease,’’ ‘‘colitis, ulcerative,’’ ‘‘IBD,’’ ‘‘CD,’’ ‘‘UC,’’
‘‘ulcerative colitis,’’ ‘‘Crohn’s,’’ ‘‘Helicobacter pylori,’’
‘‘H. pylori,’’ and ‘‘HP.’’ Boolean operators (AND, OR,
NOT) were used to narrow and widen the search results.
The titles and abstracts from the search results were exam-
ined closely for potential inclusion in the study. Addition-
ally, the references from selected articles were examined as
a further search tool. We also consulted experts in the field
to identify additional published and unpublished studies.
Last, we searched the abstracts presented at Digestive Dis-
ease Week, United European Gastroenterology Week, and
the American College of Gastroenterology Annual Scien-
tific Meeting from 2003–2007.
Study Selection
For inclusion in the systematic review, a study had to
meet the following criteria established by the study team:
1) H. pylori infection diagnosed by serology (IgG anti-
body), urea breath test (UBT), fecal antigen test (FAT),
rapid urease test (RUT), or histology; 2) inclusion of a con-
trol group; 3) IBD and control groups were similar in age,
sex, and from the same catchment area; 4) studies of
human; and 5) data were reported that were sufficient to
calculate H. pylori infection rates in both the IBD and con-
trol groups. Studies were excluded if they used data from a
previously published study.
Data Extraction
To reduce reporting bias and error in data collection,
2 independent reviewers (J.L. and M.D.) extracted data
from selected studies using standardized data extraction
forms. These forms, created by the study team, included
the: a) authors; b) title; c) year of publication; d) journal;
e) study design; f) inclusion and exclusion criteria; g)
method by which H. pylori infection was diagnosed; h)
method by which IBD was diagnosed; i) number of
patients with Crohn’s disease (CD) and within this group,
the number who were H. pylori-positive and -negative; j)
number of patients with ulcerative colitis (UC) and within
this group, the number who were H. pylori positive and
negative; k) number of patients in the control group and
within this group, the number of patients who were
H. pylori-positive and -negative; l) reported previous use of
antibiotics, and specifically antibiotics used to treat
H. pylori, in the IBD and control groups; and m) reported
previous use of immunosuppressive agents in the IBD
group, specifically steroids, 5-aminosalicylates (5-ASAs),
and tumor necrosis factor alpha (TNF-a) antibody medica-
tions. If needed, authors were contacted regarding specific
questions relating to their study. The independent reviewers
conferred after data extraction was complete, discrepancies
were identified, and review of the relevant article led to
consensus.
Statistical Analysis
The primary outcome of this analysis was the relative
risk (RR) of H. pylori infection in IBD versus controls. RR
was used to describe the ratio of the probability of the
H. pylori infection occurring in IBD patients versus the
controls. We calculated the RR with a 95% confidence
interval (CI) based on a random-effects model as described
by Mantel–Haenszel. Meta-analysis was performed with
the metan command in Stata 10.1 (StataCorp, College Sta-
tion, TX). Analysis with a funnel plot, Begg’s test, and
Egger’s test were used to assess publication bias. Subgroup
analyses were also performed. An I2 statistic was used to
measure the proportion of inconsistency in individual stud-
ies that could not be explained by chance.24 Any heteroge-
neity identified would prompt subgroup analysis in an
attempt to explain these findings.
FIGURE 1. A proposed model of H. pylori’s effect on host
immune regulation. H. pylori, through its interaction with den-
dritic cells (DC), is able to upregulate regulatory T-cells. This
upregulation leads to decreased production of proinflamma-
tory cytokines. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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Assessment of Study Quality
Each study chosen for review was carefully assessed
for study quality by the study team. Study quality was
assessed using the following criteria: 1) study design; 2)
method of H. pylori diagnosis; 3) method of IBD diagno-
sis; 4) method of patient enrollment (consecutive versus
selected); and 5) whether H. pylori infection rate was the
primary or secondary outcome of the study.
RESULTS
Search Results
Our initial search strategy yielded 369 potential
articles for inclusion. After detailed analysis of selected
articles, 29 articles were reviewed in detail. Subsequently,
6 articles25–30 did not meet inclusion criteria. The reasons
for exclusion included: 1 study included a control group
from a different catchment area from the IBD group, and
also differed significantly in mean age,25 1 study examined
a control group with known H. pylori infection,26 1 study
was published in abstract form only and the H. pylori
infection rates in the control and IBD groups could not be
calculated,27 2 studies did not provide data on H. pylori
FIGURE 2. Flow diagram of studies identified in the system-
atic review.












el-Omar et al. (32) 1994 Poland Single 210 110 (63/47) 100 38.7/47.3 NR
Mantzaris et al. (35) 1995 Greece Single 210 90 (0/90) 120 NR NR
Meining et al. (50) 1997 Germany Multi 72 36 (36/0) 36 34.3 34.4
Oberhuber et al. (41) 1997 Germany Single 275 82 (75/7) 193 NR NR
Parente et al. (33) 1997 Italy Single 432 216 (123/93) 216 38.6/39.9 NR
Wagtmans et al. (31) 1997 Netherlands Single 663 386 (386/0) 277 NR NR
Duggan et al. (52) 1998 U.K. Single 431 257 (87/170) 174 NR NR
Corrado et al. (43) 1998 Italy Single 90 30 (NR/NR) 60 12.2 7.3
D’Inca et al. (42) 1998 Italy Single 151 108 (67/41) 43 40/37 38
Pearce et al. (34) 2000 U.K. Single 133 93 (42/51) 40 42/46 43
Parente et al. (46) 2000 Italy Single 361 220 (141/79) 141 NR NR
Parlak et al. (37) 2001 Turkey Single 188 111 (45/66) 77 37.2/41.9 37
Vare et al. (40) 2001 Finland Single 349 279 (94/185) 70 43 NR
Feeney et al. (39) 2002 U.K. Single 552 276 (139/137) 276 NR NR
Furusu et al. (51) 2002 Japan Single 75 50 (25/25) 25 NR NR
Guslandi et al. (38) 2002 Italy Single 90 60 (60/0) 30 NR NR
Pascasio et al. (44) 2003 U.S.A. Single 486 56 (56/0) 382 NR NR
Piodi et al. (47) 2003 Italy Single 144 72 (32/40) 72 48/49 NR
Triantafillidis et al. (36) 2003 Greece Single 243 116 (39/77) 127 42 44
Pronai et al. (48) 2004 Hungary Single 333 133 (51/82) 200 34.2/38.4 36.3
Oliveira et al. (53) 2004 Brazil Single 116 42 (0/42) 74 38.9 49.4
Oliveira et al. (49) 2006 Brazil Single 117 43 (43/0) 74 40.9 49.4
Sladek et al. (45) 2007 Poland Single 198 94 (50/44) 194 12.9 13.6
CD, Crohn’s disease; UC, ulcerative colitis; NR, not reported.
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infection rates,28,29 and 1 study used IgA serology as a
diagnostic method for H. pylori infection.30 Therefore, 23
studies31–53 with 5903 patients fulfilled the inclusion crite-
ria for the review (Fig. 2).
Study Characteristics
The characteristics of the included studies are sum-
marized in Tables 1 and 2. The results of each study are in
Table 3. The largest study examining the relationship
between H. pylori infection and incidence of IBD was con-
ducted in the Netherlands by Wagtmans et al.31 The
authors recovered frozen sera from 386 patients with
known CD and 277 controls, and the sera was tested for
the presence of IgG and IgA antibodies. Interestingly, the
sera from the patients with Crohn’s were recovered from
frozen storage and in some instances had been there for
20 years. Unlike Halme et al,30 which was excluded from
our analysis, the authors provided data on the number of
IgG-positive, IgA-positive, and IgG/IgA-positive patients.
Therefore, we were able to exclude the IgA-positive
patients in our analysis. Overall, 12.1% of IBD patients
were infected with H. pylori, while 35.4% of the control
group were found to have H. pylori infection.
The earliest study examining H. pylori infection rates
and IBD was published in 1994 by el-Omar et al.32 In this
Polish study, el-Omar et al investigated 110 patients with
IBD and 100 age- and sex-matched controls. H. pylori was
diagnosed by the presence of IgG serologic antibodies.
Prior to the study the authors studied serum samples from
patients from their hospital with known H. pylori infection
diagnosed by UBT and histology. By performing IgG anti-
body titers in these patients, they were able to show an
IgG titer of 15 U/mL or above had a sensitivity and speci-
ficity of 96% and 84%, respectively, for H. pylori infec-
tion, thereby increasing the specificity of the serologic test.
Therefore, they used this value as the cutoff for diagnosing
H. pylori infection in the IBD and control groups. Overall,
22% of the IBD patients were positive for H. pylori, while
52% of the patients in the control group were H. pylori-
positive. The authors, in a post-hoc analysis, did report a
possible relationship between the lower prevalence of
H. pylori infection in the IBD groups and current or previ-
ous use of sulfasalazine. This inverse relationship between
TABLE 2. Quality Assessment of the Included Studies
Author H.P.a Diagnosis IBD Diagnosis Study Type Patient Enrollment Outcome
el-Omar et al. (32) IgG Chart review Prospective Random Primary
Mantzaris et al. (35) Histology/RUT Not reported Prospective Consecutive Primary
Meining et al. (50) Histology Histology Prospective Consecutive Secondary
Oberhuber et al. (41) Histology Histology Prospective Consecutive Secondary
Parente et al. (33) IgG/histology Chart review Prospective Consecutive Primary
Wagtmans et al. (31) IgG Chart review Retrospective Random Primary
Duggan et al. (52) IgG Chart review case-series Consecutive Primary
Corrado et al. (43) IgG Histology Prospective Consecutive Secondary
D’Inca et al. (42) Histology Chart review Prospective Consecutive Primary
Pearce et al. (34) IgG/UBT Radiology/histology Prospective Consecutive Primary
Parente et al. (46) UBT/histology Chart review Prospective Consecutive Primary
Parlak et al. (37) Histology Not reported Prospective Not reported Primary
Vare et al. (40) IgG Chart review Prospective previous study Primary
Feeney et al. (39) IgG Clinical criteriab Case-series Matched Primary
Furusu et al. (51) IgG/histology Histology Prospective Not reported Secondary
Guslandi et al. (38) IgG Not reported Not reported Not reported Primary
Pascasio et al. (44) Histology Histology Retrospective Consecutive Secondary
Piodi et al. (47) UBT Chart review Prospective Consecutive Primary
Triantafillidis et al. (36) IgG Chart review Prospective Not reported Primary
Pronai et al. (48) UBT Histology Prospective Not reported Primary
Oliveira et al. (53) IgG/UBT Histology Prospective Not reported Primary
Oliveira et al. (49) UBT Histology Prospective Not reported Primary
Sladek et al. (45) Histology/RUT Clinical/histology/serology Not reported Consecutive Primary
aH.P., Helicobacter pylori.
bClinical criteria: authors state diagnoses were made according to ‘‘conventional clinical criteria.’’
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previous or current sulfasalazine use and H. pylori infec-
tion was reported by 3 other included studies.33–35 One of
these studies35 was a letter to the editor (one of 3 letters to
the editor included in our analysis).36,37 In this study,
Mantzaris et al35 reported H. pylori infection rates, based
on histological analysis, of 30% in UC patients versus 53%
in the control group (patients with irritable bowel syn-
drome). However, 7 of the included studies found no
relationship between sulfasalazine use and incidence of
H. pylori infection.36–42
Three of the included studies examined the pediatric
population exclusively.43–45 Among these is the only study
conducted in North America. Pascasio et al44 identified 56
cases of CD through retrospective analysis of 438 consecu-
tive gastric biopsies with evidence of inflammation. In a
secondary analysis, the authors examined each specimen
for the presence of H. pylori and found that 32.1% of IBD
patients were H. pylori-positive, while 34.0% of the speci-
mens with no evidence of IBD had evidence for H. pylori
infection.
Five of the included studies commented on previous
H. pylori treatment.39,42,46–48 Of these, 4 studies excluded
any patients who had been previously tested or treated for
H. pylori.42,46–48 Parlak et al37 excluded any patients who
had ever received proton-pump inhibitors or antibiotics;
therefore, one can assume these patients had never received
treatment for H. pylori. Feeney et al,39 in an attempt to
assess different childhood risk factors for the development
of IBD, included patients who had previously been treated
for H. pylori. However, in a subgroup analysis, they could
not account for the difference in H. pylori infection rates
between the 2 groups based on previous H. pylori treat-
ment. Two studies excluded any patients who had ever
received certain antibiotics such as flagyl, ciprofloxacin, or
clarithromycin, yet they did not specify previous treatment
for H. pylori.36,38 Oliveira et al49 and Sladek et al45
excluded patients who received any antibiotics 3 months
prior to H. pylori testing, yet the authors did not comment
on antimicrobial exposure prior to this. Meining et al50
excluded patients taking proton-pump inhibitors, antibiot-
ics, or bismuth at the time of diagnosis, yet no mention of
previous use was made.
Meta-Analysis of RR
Overall, a total of 27.1% of IBD patients had evi-
dence of H. pylori infection, while 40.9% of patients in the
control group were found to have H. pylori infection. The
RR of H. pylori in IBD patients compared to controls was
0.64 (95% CI: 0.54–0.75) (Fig. 3). Subgroup analyses
revealed a trend toward a greater effect for CD (RR: 0.60,
95% CI: 0.49–0.72) when compared to UC (RR: 0.75, 95%
CI: 0.62–0.90). There was significant heterogeneity in the
included studies (I2 ¼ 75.8%). Furthermore, analysis of the
funnel for publication bias suggested a possible bias against
small studies demonstrating high RR (Fig. 4).
We conducted multiple subgroup analyses in an
attempt to explain the observed heterogeneity. We divided
the data based on the method of H. pylori diagnosis (serol-
ogy versus UBT, FAT, RUT, or culture), method of IBD
diagnosis (clinical versus pathological), study location
(Eastern versus Western hemisphere), and study population
age (pediatrics versus adult). None of these subgroup anal-
yses were able to account for the observed heterogeneity.
Subsequently, we separated the dataset into CD and UC
and reperformed each of the aforementioned subgroup
analyses. This analysis revealed a statistically significant
reduction in the RR of H. pylori infection in CD patients
diagnosed with H. pylori by nonserologic methods (RR:
0.71, 95% CI: 0.58–0.87; I2: 54%)
DISCUSSION
Our systematic review of the literature has identified
numerous studies examining the relationship between







el-Omar et al. (32) 21.8 (14.9/27.0) 52
Mantzaris et al. (35) 30.0 (NR/30.0) 52.5
Meining et al. (50) 8.3 (8.3/NR) 36.1
Oberhuber et al. (41) 30.5 (33.3/0.0) 35.2
Parente et al. (33) 48.1 (40.7/55.9) 58.8
Wagtmans et al. (31) 12.2 (12.2/NR) 35.4
Duggan et al. (52) 34.2 (33.3/34.7) 36.2
Corrado et al. (43) 0.0 (NR/NR) 23.3
D’Inca et al. (42) 28.7 (28.4/29.3) 39.5
Pearce et al. (34) 17.2 (11.9/21.6) 25
Parente et al. (46) 38.2 (33.3/46.8) 50.3
Parlak et al. (37) 66.7 (62.2/69.7) 63.6
Vare et al. (40) 24.4 (12.9/29.7) 37.1
Feeney et al. (39) 0.05 (0.05/NR) 15.8
13.9 (NR/13.9) 15.3
Furusu et al. (51) 29.4 (34.6/24.0) 52
Guslandi et al. (38) 15.0 (15.0/NR) 36.7
Pascasio et al. (44) 32.1 (32.1/NR) 46.1
Piodi et al. (47) 47.2 (53.1/42.5) 61.1
Triantafillidis et al. (36) 34.5 (NR/NR) 55.1
Pronai et al. (48) 12.8 (13.7/12.2) 39
Oliveira et al. (53) 52.4 (NR/52.4) 51.4
Oliveira et al. (49) 51.2 (51.2/NR) 70.3
Sladek et al. (45) 9.6 (14.0/0.05) 38.5
NR, not reported; H.P., Helicobacter pylori.
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H. pylori infection and IBD, the majority of which find a
lower rate of H. pylori infection in IBD patients as com-
pared to controls. Thirteen of the 23 studies found a statis-
tically significant RR less than 1 for H. pylori infection in
IBD patients versus controls, while none of the included
studies found a statistically significant RR greater than 1.
Our meta-analysis suggests a potential protective benefit of
H. pylori infection against the development of IBD; how-
ever, significant heterogeneity and the possibility of publi-
cation bias limit our certainty in this association.
Mechanistic support for the association between the
possible protective benefit of H. pylori infection against
IBD is emerging. Rad et al20 demonstrated that H. pylori-
infected individuals expressed higher levels of Foxp3, a T-
cell regulatory (Treg) marker, and that the depletion of
Tregs resulted in a higher degree of gastric inflammation
and reduced bacterial colonization. Furthermore, the impor-
tance of Tregs in the pathogenesis of IBD can be illustrated
by the development of spontaneous colitis in mice deficient
of IL-10, a key regulatory cytokine for Treg function.54 It
has also been shown that adoptive transfer of Tregs inhibits
the development of experimental colitis in several mod-
els,55,56 suggesting that Tregs play an integral role in pre-
venting the development of colitis.57 Further work attempt-
ing to define the possible role of Tregs on colitis is needed.
The data on the incidence of H. pylori infection and
IBD found in the literature has several limitations. Most of
the studies did not comment on the participants’ previous
FIGURE 3. Forest plot of rate of
H. pylori infection in patients with
IBD versus controls.
FIGURE 4. Funnel plot analysis.
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history of treatment for H. pylori infection. It is therefore
possible that study participants had been treated for
H. pylori prior to entering the study, thereby producing a
falsely low H. pylori infection rate. Additionally, our anal-
ysis included studies that used IgG serological antibodies
as the diagnostic method for H. pylori. Given the high sen-
sitivity and lower specificity of serologic testing, our
results may include false-positives. Furthermore, many of
the studies did not clearly identify the criteria for establish-
ing an IBD diagnosis. Many studies referred to chart
review and characteristic clinical and radiological findings
associated with IBD as the standard for inclusion, yet few
commented on personal review of the endoscopic findings
or histology. Last, as with any study examining the associ-
ation between 2 entities, causality cannot be inferred from
the results.
Ideally, future studies should address these limita-
tions. An ideal study examining the relationship between
H. pylori infection and IBD would be conducted at the
time of IBD diagnosis. After confirming the diagnosis of
IBD through review of the endoscopic and histological
findings, diagnostic testing for H. pylori with UBT, RUT,
or histology would be initiated. In patients found to be
H. pylori-positive, the presence or absence of cagAþ would
be investigated, as the possible protective benefits of
H. pylori against other autoimmune diseases come from
cagAþ strains.15,58,59 The mechanism for the inverse asso-
ciation between cagAþ strains of H. pylori and the lower
incidence of autoimmune disease has yet to be defined.
Chen and Blaser59 suggest the intense host responses to
specifically cagAþ H. pylori strains may further alter
TH1- and TH2-type immune responses with subsequent
induction of immunoregulatory lymphocytes. Controls
who are age- and sex-matched to the IBD group would be
selected from the same area as the IBD group and tested
for H. pylori by the same method. In both groups, a thor-
ough history examining previous H. pylori treatment
would be obtained.
In summary, our review suggests a possible protec-
tive benefit of H. pylori against the development of IBD.
However, significant variation among the studies and the
possibility of publication bias limit the certainty of this
association. Therefore, further clinical studies investigating
the effect of H. pylori eradication on the development of
IBD are warranted. Because environmental hygiene and
intestinal microbiota may be strong confounders, further
mechanistic studies in H. pylori mouse models are also
necessary to further define the mechanism of this nega-
tive association. If it is found that H. pylori does indeed
protect against IBD, this will have profound effects
not only on the way we approach H. pylori testing
and treatment, but also the way we approach the treat-
ment of IBD.
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